

## Media Release

### Straumann invests in RODO Medical

- *Straumann purchases approximately 12% of RODO Medical's shares for an undisclosed sum.*
- *RODO Medical's highly innovative Smileloc™ System could have an important impact on implant prosthetic design, replacing cement and screws in implant restorations.*

**Basel/Sunnyvale, 13 August 2014:** Straumann, a global leader in replacement, restorative and regenerative dentistry, and RODO Medical, Inc., a privately-held company developing innovative devices in dental implant restorations, have signed an agreement under which Straumann has acquired approximately 12% of RODO Medical's shares for an undisclosed sum.

#### **The innovative Smileloc™ System**

At the heart of the RODO Medical's Smileloc™ System is a retention mechanism utilizing shape memory properties of 'nitinol', a nickel-titanium alloy, which has been safely used for decades in stents and other medical devices, including orthodontic archwire and edotonic files. With Smileloc™, the crown or denture (prosthesis), can simply be fixed to the implant abutment without the need for cement or retaining screws. The Smileloc™ System eliminates disadvantages associated with cement and screws, and significantly simplifies the existing implant restoration process by allowing quick and easy removal of the prosthesis. This in turn can dramatically cut procedure time and cost without sacrificing esthetics. For more information, please visit [www.rodomedical.com](http://www.rodomedical.com).

Straumann's CEO **Marco Gadola** commented: "Smileloc is an innovative concept designed to address a significant need. The first clinical results are promising and I agree with the developers that, when it becomes commercially available, it might substitute some of the current fixture technology. RODO Medical's entrepreneurial and scientific approach to innovation makes them an attractive partner for Straumann and we are excited about working together with them to change paradigms in dentistry".

RODO Medical's CEO **Young Seo** commented: "We are very excited about Straumann's investment in the company. Straumann is the global market leader in the dental implant industry and highly respected for its reliable products and responsible innovations".

#### **About RODO Medical**

RODO Medical is an innovative medical device company dedicated to improving the quality of life of patients and dentists. The company was founded in 2009 and is located in Sunnyvale, California. RODO Medical has developed novel retention devices in implant dentistry. The Smileloc™ System is used in permanent fixed restorations with dental implants and the Smileclip™ System is used in removable dentures with dental implants. The Smileloc™ System is not yet cleared by the FDA for marketing in the US, but has marketing clearance in Europe (CE Mark).



### About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2200 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners.

---

**Straumann Holding AG**, Peter Merian-Weg 12, 4002 Basel, Switzerland.

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

E-mail: [corporate.communication@straumann.com](mailto:corporate.communication@straumann.com) or [investor.relations@straumann.com](mailto:investor.relations@straumann.com)

Homepage: [www.straumann.com](http://www.straumann.com)

### Contacts:

#### Straumann

Corporate Communication:

Mark Hill, +41 (0)61 965 13 21

Thomas Konrad, +41 (0)61 965 15 46

Investor Relations:

Fabian Hildbrand, +41 (0)61 965 13 27

#### RODO Medical Inc.

Tania Segovia, +1 408 245 7636; [info@rodomedical.com](mailto:info@rodomedical.com)

### Disclaimer

This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Straumann Media Releases subscription:

[www.straumann.com/en/home/investor-relations/ir-contacts-and-services/subscription.html](http://www.straumann.com/en/home/investor-relations/ir-contacts-and-services/subscription.html)

Straumann Social Media Channels

<http://www.straumann.com/en/home/about-straumann/social-media.html>

RSS feed subscription:

[www.straumann.com/en/home/media/media-releases.news.rss](http://www.straumann.com/en/home/media/media-releases.news.rss)

###